Kadcyla is currently being funded through the Cancer Drugs Fund (CDF) and those who are currently being treated with it will not lose access. However, unless this draft decision is reversed ahead of its final consultation, this drug will not be available to new patients in England in the future, despite currently being available in this and many other European countries. The decision comes following the failure of NICE and the manufacturer, Roche Pharmaceuticals, to reach an agreement that would see Kadcyla remain available on the NHS.
The latest lucky winners from 21 October 2016:
Our £10 runners up:
The Pink Ribbon Lottery is Breast Cancer Now’s weekly lottery. For just £1 a week you can be in with the chance of winning one of 18 cash prizes every Friday!
After Dr Mogensen obtained her PhD from the University of Manchester, she moved to the University of St Andrews to study how ‘microtubules’ – an important component of the cell’s skeleton – are organised in ‘epithelial’ cells, such as those that line the breast ducts. Later, Dr Mogensen joined the University of Dundee as lecturer before moving in 2001 to the University of East Anglia, where she is now a Senior Lecturer in Cell and Developmental Biology.